title: Clinical features and autonomic testing predict survival in multiple system atrophy.
abstract: Multiple system atrophy is characterized by autonomic failure along with motor symptoms of parkinsonism and/or cerebellar ataxia. There are differing reports on the influence of certain clinical features, including motor subtype (multiple system atrophy-parkinsonism versus multiple system atrophy-cerebellar ataxia), age of onset, gender, and early autonomic symptoms, on the survival in patients with multiple system atrophy. We sought to evaluate overall survival and predictors of survival in a large cohort of patients with multiple system atrophy seen at a single referral centre where objective autonomic testing is routinely performed for this indication. All cases of multiple system atrophy evaluated at Mayo Clinic, Rochester and assessed with an autonomic reflex screen between January 1998 and December 2012 were retrospectively reviewed. A total of 685 patients were identified; 594 met criteria for probable multiple system atrophy, and 91 for possible multiple system atrophy. Multiple system atrophy-parkinsonism was the predominant subtype in 430 patients (63%). Average age of onset was earlier in multiple system atrophy-cerebellar ataxia (58.4 years) compared to multiple system atrophy-parkinsonism (62.3 years; P < 0.001). Median disease duration from symptom onset to death was 7.51 years (95% confidence interval 7.18-7.78) while time from diagnosis to death was 3.33 years (95% confidence interval 2.92-3.59). There was no difference in survival between motor subtypes of multiple system atrophy (P = 0.232). An initial motor symptom was most common (61%) followed by autonomic onset (28%) and combined motor and autonomic symptoms (11%). The initial onset of either motor or autonomic symptoms did not influence length of survival. However, a number of clinical and autonomic laboratory features predicted unfavourable survival in a univariate analysis. A multivariate model retained the following unfavourable predictors of survival: (i) falls within 3 years of onset (hazard ratio 2.31, P < 0.0001); (ii) bladder symptoms (hazard ratio 1.96, P < 0.0001); (iii) urinary catheterization within 3 years of symptom onset (hazard ratio 1.67, P < 0.003); (iv) orthostatic intolerance within 1 year of symptom onset (hazard ratio 1.28, P < 0.014); (v) older age of onset (hazard ratio 1.02, P = 0.001); and (vi) degree of autonomic failure as measured by a validated composite autonomic severity score (hazard ratio 1.07, P < 0.0023). We conclude that carefully selected clinical features can be used to predict survival in patients with multiple system atrophy. Autonomic testing adds an additional, independent predictor of survival, demonstrating its value not only in the diagnosis of multiple system atrophy but also as prognostic marker.
authors.affiliation: 1 Department of Neurology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Coon
authors.affiliation: 1 Department of Neurology, Mayo Clinic, Rochester, MN, USA.
authors.forename: David M
authors.initials: DM
authors.lastname: Sletten
authors.affiliation: 1 Department of Neurology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Mariana D
authors.initials: MD
authors.lastname: Suarez
authors.affiliation: 2 Department of Clinical Statistics, Mayo Clinic, Rochester, MN, USA.
authors.forename: Jay N
authors.initials: JN
authors.lastname: Mandrekar
authors.affiliation: 1 Department of Neurology, Mayo Clinic, Rochester, MN, USA.
authors.forename: J Eric
authors.initials: JE
authors.lastname: Ahlskog
authors.affiliation: 1 Department of Neurology, Mayo Clinic, Rochester, MN, USA.
authors.forename: James H
authors.initials: JH
authors.lastname: Bower
authors.affiliation: 1 Department of Neurology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Joseph Y
authors.initials: JY
authors.lastname: Matsumoto
authors.affiliation: 1 Department of Neurology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Michael H
authors.initials: MH
authors.lastname: Silber
authors.affiliation: 1 Department of Neurology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Eduardo E
authors.initials: EE
authors.lastname: Benarroch
authors.affiliation: 1 Department of Neurology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Robert D
authors.initials: RD
authors.lastname: Fealey
authors.affiliation: 1 Department of Neurology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Paola
authors.initials: P
authors.lastname: Sandroni
authors.affiliation: 1 Department of Neurology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Phillip A
authors.initials: PA
authors.lastname: Low
authors.affiliation: 1 Department of Neurology, Mayo Clinic, Rochester, MN, USA singer.wolfgang@mayo.edu.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Singer
mesh_terms: D000328:Adult; D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D001341:Autonomic Nervous System / Q000503:physiopathology*; D001342:Autonomic Nervous System Diseases / Q000150:complications / Q000175:diagnosis* / Q000503:physiopathology; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019578:Multiple System Atrophy / Q000150:complications / Q000175:diagnosis* / Q000401:mortality / Q000503:physiopathology*; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis
keywords: ataxia; autonomic; multiple system atrophy; parkinsonism